Identical, unique p53 mutations in a primary ovarian mucinous adenocarcinoma and a synchronous contralateral ovarian mucinous tumor of low malignant potential suggest a common clonal origin

Human Pathology

Volumn 28, Issue 5, 1997, Pages 626-630

  Werness, Bruce A ^a   Dicioccio, Richard A ^a   Piver, M Steven ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

clonality; low malignant potential; ovarian neoplasms; p53

Indexed keywords

PROTEIN P53;

ADULT; ARTICLE; CASE REPORT; FEMALE; GENE MUTATION; GYNECOLOGIC CANCER; HUMAN; HUMAN TISSUE; MUCINOUS CARCINOMA; MULTIPLE CANCER; OVARY ADENOCARCINOMA; PERITONEUM METASTASIS; POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 0030968793     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(97)90087-3     Document Type: Article

References (43)

1. Serov SF, Scully RE, Sobin LH: Histologic typing of ovarian tumors, in International Histological Classification of Tumors, no. 9. Geneva, World Health Organization, 1973, pp 17-18
2. Russell P, Bannatyne P (eds): Mullerian epithelial and mesenchymal tumours, in Surgical Pathology of the Ovaries. New York, Churchill Livingstone, 1989, pp 190-194
3. Puls LE, Powell DE, DePriest PD, et al: Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol Oncol 47:53-57, 1992
4. Zheng J, Wan M, Zweizig S, et al: Histologically benign or low-grade malignant tumors adjacent to high-grade ovarian carcinomas contain molecular characteristics of high-grade carcinomas. Cancer Res 53:4138-4142, 1993
5. ZhengJ, Benedict WF, Xu, H-J, et al: Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadeno-mas. J Natl Cancer Inst 87:1146-1153, 1995
6. Hart W, Norris H: Borderline and malignant mucinous tumors of the ovary: Histologic critereia and clinical behavior. Cancer 31:1031-1045, 1973
7. Hendrickson MR, Kempson RL: Well-differentiated mucinous neoplasms of the ovary, in Hendrickson MR (ed): Surface Epithelial Neoplasms of the Ovary. Philadelphia, PA, Hanley and Belfus, 1993, pp 307-334
8. DiCioccio RA, Siniscalo M: Human RNA transcripts in man-mouse somatic cell hybrids. II. Thermal denaturation studies and cot analysis. Somatic Cell Gene 1:263-279, 1975
9. Johnson DR, Levanat S, Bale AE: Direct molecular analysis of archival tumor tissue for loss of heterozygosity. Bio techniques 19:190-191, 1995
10. DiCioccio RA, Piver MS: A polymorphism in intron 2 of the TP53 gene. Clin Genet 50:108-109, 1996
11. Towbin H, Staehelin T, Gordon J: Electrophoretic transfer of proteins from polyaciylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sei U S A 76:4350-4354, 1979
12. Trimble EL, Trimble CL: Epithelial ovarian tumors of low malignant potential, in Markman M, Hoskins WJ (eds): Cancer of the Ovary. New York, NY, Raven, 1993, pp 415-429
13. Bourne TH, Whitehead MI, Campbell S, et al: Ultrasound screening for familial ovarian cancer. Gynecol Oncol 43:92-97, 1991
14. Schildkraut JM, Thompson WD: Familial ovarina cancer: A population-based case-control study. Am J Epidemiol 128456-466, 1988
15. Jenkins RB, Bartelt D, Stalboerger P, et al: Cytogenetic studies of epithelial ovarian carcinoma. Cancer Genet Cytogenet 71:76-78, 1993
16. Dodson MK, Hartmann LC, Cliby WA, et al: Comparison of loss of heterozygosity patterns in low-grade and high-grade epithelial ovarian carcinomas. Cancer Res 53:4456-4460, 1993
17. Mazars R, Pujol P, Maudelonde T, et al: p53 mutations in ovarian cancer: A late event? Oncogene 6:1685-1690, 1991
18. Okamato A, Sameshima Y, Yokoyama S, et al: Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res 51:5171-5176, 1991
19. Kupryjanczyk J, Thor AD, Beauchamp R, et al: p53 gene mutations and protein accumulation in human ovarian cancer. Proc Nail Acad Sei U S A 90:4961-4965, 1993
20. Wertheim I, Muto MG, Welch WR, et al: p53 gene mutations in human borderline epithelial ovarian tumors. J Natl Cancer Inst 86:1549-1551, 1994
21. Kappes S, Milde-Langosch K, Kressin P, et al: p53 mutations in ovarian tumors, detected by temperature-gradient gel electrophoresis, direct sequencing and immunohistochemistry. Int J Cancer 64:52-59, 1995
22. Kupryjanczyk J, Bell DA, Dimeo D: p53 gene analysis of ovarian borderline tumors and stage I carcinomas. HUM PATHOL 26:387-392, 1995
23. Hutson R, Ramsdale J, Wells M: p53 protein expression in putative precursor lesions of epithelial ovarian cancer. Histopathology 27:367-371, 1995
24. Fraumeni JF, Grundy GW, Creagan ET, et al: Six families prone to ovarian cancer. Cancer 36:364-369, 1975
25. Graham JB, Graham RM, Schueller EF: Preclinical detection of ovarian cancer. Cancer 11:1414-1432, 1964
26. Gusberg SB, Deligdisch L: Ovarian dysplasia. A study of identical twins. Cancer 54:1-4, 1984
27. Resta L, Russo S, Colucci GA, et al: Morphologic precursors of ovarian epithelial tumors. Obstet Gynecol 82:181-186, 1993
28. Bell DA, Scully RE: Early de novo ovarian carcinoma: a study of 14 cases. Cancer 73:1859-1864, 1994
29. Kurman RJ, Trimble CL: The behavior of serous tumors of low malignant potential: Are they ever malignant? IntJ Gynecol Pathol 12:120-127, 1993
30. Fox H: The concept of borderline malignancy in ovarian tumours: A reappraisal. Curr Top Pathol 78:111-134, 1989
31. Scully RE: Early de novo ovarian cancer and cancer developing in benign ovarian lesions. Int J Gynecol Obstet 49S:S9-S15, 1995
32. Lash RH, Hart WR: Intestinal adenocarcinomas metastatic to the ovaries: A clinicopathologic evaluation of 22 cases. AmJ Surg Pathol 11:114-121, 1987
33. Young RH, Scully RE: Mucinous ovarian tumors associated with mucinous adenocarcinomas of the cervix: A clinicopathological analysis of 16 cases. Int J Gynecol Pathol 7:99-111, 1988
34. Young RH, Hart WR: Metastases from carcinomas of the pancreas simulating primary mucinous tumors of the ovary. Am J Surg Pathol 13:748-756, 1989
35. Young CW, Warrell RP Jr: Differentiating agents, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, Philadelphia, PA, Lipincott, 1993, pp 2636-2646
36. Haas R: Retrodifferentiation and cell death. Grit Rev Oncogene 5:359-371, 1994
37. Stanbridge EJ, Der CJ, Doersen CJ: Human cell hybrids: Analysis of transformation and tumorigenicity. Science 215:252-259, 1982
38. Podesta AH, Mullins J, Pierce GB, et al: The neurala-stage mouse embryo in control of neuroblastoma. Proc Nad Acad Sei USA 81:7608-7611, 1984
39. Cho Y, Gorina S, Jeffrey PD, et al: Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations Science 265:346-355, 1994
40. Kohler MF, Marks JR, Wiseman RW, et al: Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 85:1513-1519, 1993
41. McManus DT, Yap EPH, Maxwell P, et al: p53 expression, mutation, and allelic deletion in ovarian cancer. J Pathol 174:159-168, 1994
42. Chemeris G, Loktinov A, Rempel A, et al: Elevated content of p53 protein in the absence of p53 gene mutations as a possible prognostic marker for human renal cell tumors. Virchows Archiv 426:563-569, 1995
43. Lane DP: p53 and human cancers. Br Med Bull 50:582-599, 1994